Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63 ; Mnemonic : ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announces today that it has received notification of the allocation of financial support from the Deep Tech Development Fund. The funding is granted through a combination of grants and a repayable advance to finance R&D investment. This support is fina